help me understand MASH, I have read the wiki twice
Quick one. Canada here.
MASH works very differently where I live than in the threads that dominate the front page, and I keep seeing people confidently given advice that simply does not apply outside the US.
Specifics: the route I used took 11 weeks and cost roughly what I expected. The admin was worse than the cost. The thing that would have saved me the most time was knowing which document to ask for at the start.
Happy to answer questions from anyone in the same jurisdiction.
best — the order this archive was captured in
The thing nobody prepared me for was the quiet. Not the appetite, the quiet. The constant negotiation in my head about food just stopped.
glucagon co-agonism has a different safety story
Yeah, glucagon co-agonism is genuinely different.
Week 51 for me and the honest summary is: 47kg down, the food-noise thing manageable, and I have thought about food maybe four times today.
not approved, descriptive posts only
rodent dual agonist is investigation only
the GLP-1/glucagon dual is glucagon, different from GIP/GLP-1
My version of this: I was so worried about the injection that I put it off for eleven days. The injection is the easiest part.
hepatic fat and MASH are the story
Strongly agree. The safety story is separate.
the GLP-1/glucagon dual is hepatic fat, different from GIP/GLP-1
rodent biopsy is investigation only
My version of this: I was so worried about the injection that I put it off for eleven days.
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
I am going to push back on this slightly.
Removed a chain here. The rule is one line long and it is not negotiable.
rodent dual agonist is investigation only
the MASH indication changes the risk calculus
Small correction: the trial was 13 weeks, not 17. Does not change your point but people will quote it.
That is net peptide content, not purity. Different number, different meaning.
not approved, descriptive posts only
This is correct. Do not generalise from tirzepatide.
the MASH indication changes the risk calculus
This is correct.
Disagree on that part. 95.1% and 98.9% on the same vial is normal.
glucagon injection is a different vector than GLP-1
Phase 24 or 40?
Phase 24 or 40?
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
Strongly agree. The safety story is separate.
Strongly agree.
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
This is correct. Do not generalise from tirzepatide.
- 1I am going to push back on this slightly.11 comments in this branch · started by u/samir_falk
- 2My version of this: I was so worried about the injection that I put it off…6 comments in this branch · started by u/patient_labslip_log